{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:11:26Z","timestamp":1776265886581,"version":"3.50.1"},"reference-count":36,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"4","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"Background: To explore the expression levels of resistin (RETN), hypoxia-inducible factor-la (HIF -l<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span> ), and peroxi-some proliferator-activated receptor g coactivator-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span> (PGCip ) in gouty arthritis (GA) patients and to analyse their cor-relations with the degree of joint destruction. Methods: The GA group consisted of 134 patients with GA who were admitted to the hospital between January 2023 and October 2024, while the control group consisted of 134 healthy patients who underwent physical examination in the hospital over the same time period. Serum PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span>, and RETN expression levels were compared. The expression levels of PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, HIF-1a and RETN in the serum and synovial fluid of patients with different clinical characteristics in the GA group were compared. The degree of joint destruction was categorised into 78 cases in the severe GA subgroup and 56 cases in the mild GA subgroup based on the VAS score of the chief complaint pain scale. Compared with PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span>, RETN, and bone destruction factors [<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>-crosslinking degradation products (P-CTX), tartrate-resistant acid phosphatase-5b (TRACP5b), and nuclear factor p receptor activator ligand (RANKL)], and inflammatory factors with different degrees of joint destruction, the expression levels of 1p (IL-1 <span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>) were analysed. The correlations between PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span>, and RETN in serum and synovial fluid, as well as the degree of joint destruction, bone destruction factors, and inflamma-tory factors, were analysed. Results: The expression level of serum PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span> in the GA group was lower than that in the control group, while the expression levels of serum HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span> and RETN were greater than those in the control group (P&lt; 0.05). The expression levels of PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span> in the serum of GA patients at different clinical stages, affected joints, disease courses and annual attack frequencies. The expression levels of <span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>-CTX and TRACP5b in the serum of GA patients at different clinical stages, affected joints, disease courses and annual attack frequencies, and in the severe GA subgroup were greater than those in the mild GA subgroup (P&lt; 0.05). RANKL expression was lower than in the mild GA subgroup (P&lt; 0.05). The serum and synovial fluid levels of PGC-1 <span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, P-CTX, TRACP5b, TNF-<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span>, and IL-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span> were negatively cor-related with the degree of joint destruction and positively cor-related with the level of RANKL. HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span> and RETN exhibited a negative correlation with RANKL and a positive correlation with the degree of joint degradation, as well as with <span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>-CTX, TRACP5b, TNF-<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span>, and IL-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>. Conclusions: PGC-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b2<\/span>, HIF-1<span style=\"color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);\">\u03b1<\/span> and RETN are abnormally expressed in patients with GA and are closely related to the degree of joint destruction, bone destruction factors and inflammatory factors. They are expected to become reli-able indicators for evaluating the occurrence and progres-sion of GA.<\/jats:p>","DOI":"10.5937\/jomb0-60976","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:27Z","timestamp":1761919647000},"page":"907-916","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis of PGC-1\u03b2, HIF-1\u03b1 and RETN with the degree of joint destruction in gouty arthritis"],"prefix":"10.5937","volume":"45","author":[{"given":"Jian","family":"Bian","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing Jiangbei Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University. No. 1, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University. No. 1, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing Jiangbei Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Cheng JJ, Ma XD, Ai G X, Yu Q X, Chen XY, Yan F , Li YC, Xie JH, Su ZR, Xie QF Palmatine Protects Against MSU-Induced Gouty Arthritis via Regulating the NF-B\/NLRP3 and Nrf2 Pathways. Drug Des Devel Ther 2022 Jul 2; 16: 2119-32. doi: 10.2147\/DDDTS356307. PMID: 35812134; PMCID: PMC9259749;","DOI":"10.2147\/DDDT.S356307"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X , Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting 2024, 10(1), 1256. doi: 10.36922\/ijb.1256;","DOI":"10.36922\/ijb.1256"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yin C, Liu B, Dong Z, Shi S, Peng C, Pan Y, Bi X , Nie H, Zhang Y, Tai Y Hu Q, Wang X , Shao X , An H, Fang J, Wang C, Liu B. CXCL5 activates CXCR2 in nociceptive sensory neurons to drive joint pain and inflammation in experimental gouty arthritis. Nat Commun 2024 Apr 16; 15(1): 3263. doi: 10.1038\/s41467-024-47640-7. PMID: 38627393; PMCID: PMC11021482;","DOI":"10.1038\/s41467-024-47640-7"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Deng P , Wang S, Sun X , Qi Y, Ma Z, Pan X , Liang H, Wu J, Chen Z. Global Trends in Research of Gouty Arthritis Over Past Decade: A Bibliometric Analysis. Front Immunol 2022 Jun 10; 13: 910400. doi: 10.3389\/ fim m u.2022.910400. PMID: 35757713; PMCID: PMC9229989;","DOI":"10.3389\/fimmu.2022.910400"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wu HJ, Dai WW, Wang LB, Zhang J, Wang CL. Comprehensive analysis of the molecular mechanism for gastric cancer based on competitive endogenous RNA network. World J Tradit Chin Med 2023; 9: 29-42. doi: 10.4103\/2311-8571.355010;","DOI":"10.4103\/2311-8571.355010"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yin C, Lyu Q, Dong Z, Liu B, Zhang K, Liu Z, Yu Q, Li P Wei Z, Tai Y, Wang C, Fang J, Liu W, Liu B. Well-defined alginate oligosaccharides ameliorate joint pain and inflammation in a mouse model of gouty arthritis. Theranostics 2024 May 19; 14(8): 3082-103. doi: 1 0 .7 1 50\/thno.95611. PMID: 38855180; PMCID: PMC11155397;","DOI":"10.7150\/thno.95611"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Xu H, Zhang B, Chen Y, Zeng F, Wang W, Chen Z, Cao L, Shi J, Chen J, Zhu X , Xue Y, He R, Ji M, Hua Y. Type II collagen facilitates gouty arthritis by regulating MSU crystallisation and inflammatory cell recruitment. Ann Rheum Dis 2023 Mar; 82(3): 416-27. doi: 10.1136\/ ard-2022-222764. Epub 2022 Sep 15. PMID: 36109143;","DOI":"10.1136\/ard-2022-222764"},{"key":"#cr-split#-ref8.1","doi-asserted-by":"crossref","unstructured":"Liu P , Xu Y, Ye J, Tan J, Hou J, Wang Y, Li J, Cui W, Wang S, Zhao Q. Qingre Huazhuo Jiangsuan Decoction pro-motes autophagy by inhibiting PI3K\/AKT\/m TOR signal-ing pathway to relieve acute gouty arthritis. J Ethnopharmacol 2023 Feb 10","DOI":"10.1016\/j.jep.2022.115875"},{"key":"#cr-split#-ref8.2","unstructured":"302(Pt A):115875. doi: 10.1016\/j.jep .2022.115875. Epub 2022 Oct 31. PMID: 36328206;"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Zhu R, Niu Y, Zhou W, Wang S, Mao J, Guo Y Lei Y, Xiong X , Li Y Guo L. Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 2023 Feb 14; 24(1): 124. doi: 10.1186\/s12891-023-06186-3. PMID: 36788552; PMCID: PMC9926759;","DOI":"10.1186\/s12891-023-06186-3"},{"key":"ref10","unstructured":"Luo Z, Yang F Hong S, Wang J, Chen B, Li L, Yang J, Yao Y Yang C, Hu Y, Wang S, Xu T, Wu J. Role of microRNA alternation in the pathogenesis of gouty arthritis. Front Endocrinol (Lausanne) 2022 Aug 11; 13: 967769. doi: 1 0 .3389\/fendo.2022.967769. PMID: 36034424; PMCID: PMC9402903;"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Zhao X , Li M, Lu Y, Wang M, Xiao J, Xie Q, He X , Shuai S. Sirt1 inhibits macrophage polarisation and inflamma-tion in gouty arthritis by inhibiting the MAPK\/NF-B\/AP-1 pathway and activating the Nrf2\/HO-1 pathway. Inflamm Res 2024 Jul; 73(7): 1173-84. doi: 10.1007\/s00011-024-01890-9. Epub 2024 May 13. PMID: 38739197; PMCID: PMC11214610;","DOI":"10.1007\/s00011-024-01890-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y Liu J, Luo R, Wu D, Xu P Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to pro-vide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Abdelnabi M, Leelaviwat N, Liao ED, Motamedi S, Pangkanon W, Nugent K. Daptomycin-induced rhab-domyolysis complicated with acute gouty arthritis. Am J Med Sci 2023 May; 365(5): 450-6. doi: 10.1016\/ j.am jm s.2023.01.005. Epub 2023 Jan 22. PMID: 36693494;","DOI":"10.1016\/j.amjms.2023.01.005"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bian M, Zhu C, Nie A, Zhou Z. Guizhi Shaoyao Zhimu Decoction ameliorates gouty arthritis in rats by altering gut microbiota and improving metabolic profile. Phytomedicine 2024 Aug; 131: 155800. doi: 10.1016\/ j.phymed.2024.155800. Epub 2024 Jun 3. PMID: 38851098;","DOI":"10.1016\/j.phymed.2024.155800"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wu L, Li X , Qian X , Wang S, Liu J, Yan J. Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. Vaccines (Basel) 2024 Feb 12; 12(2): 186. doi: 10.3390\/vaccines12020186. PMID: 38400169; PMCID: PMC10891594;","DOI":"10.3390\/vaccines12020186"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P Ruan X , Yan J, Liu J, Li X. Immunomodulatory factor TIM3 of cytolytic active genes affected the survival and prognosis of lung adenocarcinoma patients by multi-omics analysis. Biomedicines 2022 Sep 10; 10(9): 2248. doi: 10.3390\/biomedicines 10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ni Z, Xiao Q, Xia Z, Kuang K, Yin B, Peng D. Electroacupuncture for acute gouty arthritis: a systematic review and meta-analysis of randomised controlled trials. Front Immunol 2024 Jan 4; 14: 1295154. doi: 10.3389\/ fimmu.2023.1295154. PMID: 38239361; PMCID: PMC10794621;","DOI":"10.3389\/fimmu.2023.1295154"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Fu W, Ge M, Li J. Phospholipase A2 regulates autophagy in gouty arthritis: proteomic and metabolomic studies. J Transl Med 2023 Apr 17; 21(1): 261. doi: 10.1186\/ s12967-023-04114-6. PMID: 37069596; PMCID: PMC10108447;","DOI":"10.1186\/s12967-023-04114-6"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lee KG, Hong BK, Lee S, Lee N, Kim SW, Kim D, Kim WU. Nuclear receptor coactivator 6 is a critical regulator of NLRP3 inflammasome activation and gouty arthritis. Cell Mol Immunol 2024 Mar; 21(3): 227-44. doi: 10.1038\/s41423-023-01121 -x. Epub 2024 Jan 10. PMID: 38195836; PMCID: PMC10902316;","DOI":"10.1038\/s41423-023-01121-x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X , Luan X , Zhong Y Liu J, Yan J, Li X. Multiple omics analysis of the role of RBM10 gene instability in immune regulation and drug sensitivity in patients with lung adenocarcinoma (LUAD). Biomedicines 2023 Jun 29; 11(7): 1861. doi: 10.3390\/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Li N, Chen S, Deng W, Gong Z, Guo Y, Zeng S, Xu Q. Kaempferol attenuates gouty arthritis by regulating the balance of Th17\/Treg cells and secretion of IL-17. Inflammation 2023 Oct; 46(5): 1901-16. doi: 10.1007\/s10753-023-01849-8. Epub 2023 Jun 14. PMID: 37311931;","DOI":"10.1007\/s10753-023-01849-8"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yang XR, Jiang S, Gan CL, Huang J, Wei FS, Wang Z Y et al. Developing a novel single-marker-based method for the quantitative evaluation of the multiple active components in Corydalis yanhusuo W. T Wang. World J Tradit Chin Med 2023; 9: 43-52. doi: 10.4103\/2311-8571.364415;","DOI":"10.4103\/2311-8571.364415"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Ruan X , Wu D, Xu P Liu J, Wu D, Li X . Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs 2022 Jan 1; 33(1): e590-e603. doi: 10.1097\/CAD . 0000000000001189. PMID: 34338240; PMCID: PM C8670349;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zhang S, Li D, Fan M, Yuan J, Xie C, Yuan H, Xie H, Gao H. Mechanism of reactive oxygen species-guided immune responses in gouty arthritis and potential therapeutic targets. Biomolecules 2024 Aug 9; 14(8): 978. doi: 1 0 .3 3 90\/biom 14080978. PMID: 39199366; PMCID: PMC11353092;","DOI":"10.3390\/biom14080978"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wu L, Yang L, Qian X , Hu W, Wang S, Yan J. Mannandecorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment. J Funct Biomater 2024 Aug 16; 15(8): 229. doi: 10.3390\/jfb15080229. PMID: 39194667; PMCID: PMC11355305;","DOI":"10.3390\/jfb15080229"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Nutmakul T A review on benefits of quercetin in hyperuricemia and gouty arthritis. Saudi Pharm J 2022 Jul; 30(7): 918-26. doi: 10.'1016\/j.jsps.2022.04.013. Epub 2022 Apr 30. PMID: 35903522; PMCID: PM C9315272;","DOI":"10.1016\/j.jsps.2022.04.013"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Yu X , Wu D, Xu P , Lv L, Ruan X , Liu Q, Feng Y, Liu J, Li X . Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs 2022 Oct 1; 33(9): 943-59. doi: 10.1097\/C A D .0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PM C9481295;","DOI":"10.1097\/CAD.0000000000001319"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Li C, Wu C, Li F, Xu W, Zhang X , Huang Y, Xia D. Targeting neutrophil extracellular traps in gouty arthritis: insights into pathogenesis and therapeutic potential. J Inflamm Res 2024 Mar 19; 17: 1735-63. doi: 10.2147\/JIR.S460333. PMID: 38523684; PMCID: PMC10960513;","DOI":"10.2147\/JIR.S460333"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wu L, Chen X , Zeng Q, Lai Z, Fan Z , Ruan X , Li X , Yan J. NR5A2 gene affects the overall survival of LU AD patients by regulating the activity of CSCs through SNP pathway by O CLR algorithm and immune score. Heliyon 2024 Mar 28; 10(7): e28282. doi: 10 .1016\/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PM C11004709;","DOI":"10.1016\/j.heliyon.2024.e28282"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Chen Z, Wang W, Hua Y. Metabolic regulation of immune response and tissue remodeling in gouty arthritis (review). Crit Rev Eukaryot Gene Expr 2023; 33(5): 1-16. doi: 1 0 .1 6 15\/C ritR e vEu karyo tG e n eExp r.20 2204 6409 . PMID: 37199310;","DOI":"10.1615\/CritRevEukaryotGeneExpr.2022046409"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wu C, Chen S, Liu Y, Kong B, Yan W, Jiang T Tian H, Liu Z, Shi Q, Wang Y Liang Q, Xi X , Xu H. Cynarin suppresses gouty arthritis induced by monosodium urate crystals. Bioengineered 2022 May; 13(5): 11782-93. doi: 1 0 .1 0 8 0\/2165 5979 .20 22.207 2055 . PMID: 35546047; PMCID: PMC9275982;","DOI":"10.1080\/21655979.2022.2072055"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Du Y, Zhang Y, Jiang Z, Xu L, Ru J, Wei S, Chen W, Dong R, Zhang S, Jia T Triptolide alleviates acute gouty arthritis caused by monosodium urate crystals by modulating macrophage polarisation and neutrophil activity. Immunol Lett 2024 Oct; 269: 106907. doi: 10.1016\/ j.im let.2024.106907. Epub 2024 Aug 8. PMID: 39122094;","DOI":"10.1016\/j.imlet.2024.106907"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Yang DH, Chen HC, Wei JC. Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo-controlled clinical trial. Eur J Med Res 2023 Jan 6; 28(1): 10. doi: 10.1186\/s40001-022-00982-8. PMID: 36609359; PMCID: PMC9817311;","DOI":"10.1186\/s40001-022-00982-8"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Wu L, Li X , Yan J. Commentary: machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol 2024 Jul; 45: 101995. doi: 10.1016\/j.tranon.2024.101995. Epub 2024 May 9. P M ID :38789241;","DOI":"10.1016\/j.tranon.2024.101995"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Xu X , Qiu H. BRD4 promotes gouty arthritis through MDM2-mediated PPARg degradation and pyroptosis. Mol Med 2024 May 21; 30(1): 67. doi: 10.1186\/ s10020-024-00831-w. PMID: 38773379; PMCID: PMC11110350;","DOI":"10.1186\/s10020-024-00831-w"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Analiza korelacije PGC-1\u03b2, HIF-1\u03b1 i RETN sa stepenom o\u0161te\u0107enja zglobova kod gihta"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/60976\/29212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582604907B.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:15:52Z","timestamp":1776262552000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582604907B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-60976","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}